STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update of the expansion of clinical sites into Spain. As previously announced, the Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 ...

STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, according to a list ...

About FTSE Russell About Breast Cancer and HER2/neu Positivity Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forwardlooking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," ...

The offer and sale of the foregoing shares were made by Greenwich in a private placement under Section 4(a) (2) of the Securities Act of 1933, as amended (the "Act"), and/or Regulation D promulgated thereunder, and such securities have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act ...

Company Contact Snehal Patel Investor Relations Office: (832) 819-3232 Email: info@greenwichlifesciences.com Investor & Public Relations Contact for Greenwich LifeSciences Dave Gentry RedChip Companies Inc. Office: 1-800-RED CHIP (733 2447) Email: dave@redchip.com STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLS ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCES, INC. (Exact Name of registrant as specified in its charter) (State or other jurisdiction of incorporation or orga ...

Financial Performance and Losses - The company has incurred substantial losses since inception and anticipates continuing to incur significant losses for the foreseeable future[30]. - The company has incurred substantial losses since inception and anticipates continuing to incur significant and increasing losses for the foreseeable future[30]. Financing and Capital Requirements - The company requires significant additional financing to fund operations and complete product development, with potential delays or reductions in programs if capital is not raised[30]. - The company requires significant additional financing to fund operations and complete the development and commercialization of its product candidate[30]. Clinical Trials and Patient Enrollment - The company faces challenges in enrolling patients for clinical trials due to the limited number of patients with the diseases being studied[31]. - The company may face difficulties in enrolling patients for clinical trials due to the limited number of patients with the diseases being studied[31]. - The company relies on third parties for preclinical studies and clinical trials, and any failure by these parties could delay regulatory approval[36]. - The company relies on third parties for conducting preclinical studies and clinical trials, and any failure by these parties could delay regulatory approval[36]. - The company may encounter substantial costs and delays in the testing and approval process for its product candidates[57]. Dependency on Technologies and Market Acceptance - The company is dependent on licensed technologies, and losing these rights could harm product development capabilities[37]. - The company is dependent on licensed technologies, and losing these rights could harm its ability to develop new products[37]. - Market acceptance of the company's product candidates is crucial for commercial success, and inadequate reimbursement from payors could negatively impact business[38][39]. - The commercial success of the company depends on achieving significant market acceptance of its current and future product candidates[38]. Stockholder Returns and Dividends - The company does not intend to pay cash dividends, with returns to stockholders limited to potential increases in share price[49]. - The company does not intend to pay cash dividends on its common stock, limiting returns to stockholders to potential increases in share price[49]. Regulatory and Compliance Risks - The company must maintain compliance with Nasdaq listing standards to avoid delisting, which could adversely affect stockholder value[54]. - The company is classified as an "emerging growth company," allowing it to utilize reduced disclosure requirements, which may affect investor attractiveness[50]. - The company is classified as an "emerging growth company," allowing it to take advantage of reduced disclosure requirements[50]. Stock Price Volatility and Litigation Risks - The company may face significant stock price volatility, particularly related to clinical trials and product approvals, which could lead to litigation risks[51]. - The company may face risks related to securities class action litigation, particularly associated with stock price volatility during clinical trials[51].

Financial Performance - The company reported net losses of approximately $6.1 million for the nine months ended September 30, 2023, compared to $5.0 million for the same period in 2022, reflecting an increase in clinical expenses [39]. - The company has not generated any revenue to date and expects to continue incurring significant expenses as it develops its drug pipeline [39]. - The company incurred net cash used in operating activities of $4.32 million for the nine months ended September 30, 2023, compared to $4.03 million for the same period in 2022 [48]. - The company has a cumulative net loss from operations since its inception in 2006 and will continue to incur net losses for the foreseeable future [45]. Research and Development - Research and development expenses increased by $1.35 million, or 34%, to $5.37 million for the nine months ended September 30, 2023, primarily due to increased clinical expenses [43]. - Research and development expenses increased by $434,674, or 25%, to $2.16 million for the three months ended September 30, 2023, compared to $1.72 million for the same period in 2022 [41]. - The company is conducting a Phase III clinical trial, Flamingo-01, to evaluate the safety and efficacy of GLSI-100 in HER2/neu positive patients [38]. Cash Position and Funding - As of September 30, 2023, the company's cash totaled $9.14 million, down from $13.47 million as of December 31, 2022 [46]. - The company expects to require additional capital to meet long-term operating requirements and plans to raise funds through equity and/or debt securities [46]. General and Administrative Expenses - General and administrative expenses decreased by $1,815 to $1.13 million for the nine months ended September 30, 2023, from $1.13 million for the same period in 2022 [44].

Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCES, INC. (Exact Name of registrant as specified in its charter) (State or other jurisdiction (I.R.S. Employer of incor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCES, INC. (Exact Name of registrant as specified in its charter) (State or other jurisdiction of incorporation or orga ...